Glaukos Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US3773221029
USD
108.85
1.39 (1.29%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Glaukos Corp. stock-summary
stock-summary
Glaukos Corp.
Pharmaceuticals & Biotechnology
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.
Company Coordinates stock-summary
Company Details
229 Avenida Fabricante , SAN CLEMENTE CA : 92672-7531
stock-summary
Tel: 1 949 3679600
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 93 Schemes (63.81%)

Foreign Institutions

Held by 152 Foreign Institutions (11.54%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. William Link
Independent Chairman of the Board
Mr. Thomas Burns
President, Chief Executive Officer, Director
Dr. Gilbert Kliman
Director
Mr. Mark Foley
Independent Director
Mr. David Hoffmeister
Independent Director
Mr. Marc Stapley
Independent Director
Ms. Aimee Weisner
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
124 Million
(Quarterly Results - Jun 2025)
Net Profit:
-20 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5,272 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.36

stock-summary
Return on Equity

-12.13%

stock-summary
Price to Book

6.89